DHX30

Across TCGA pan-cancer cohorts, DHX30 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DHX30 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DHX30 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated DHX30 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and UCEC are the cancer types where DHX30 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.717	0.422	.013	12	view →
LSCC	OS	Quartile	All	0.948	0.704	.026	5	view →
UCEC	DFS	Median	All	0.784	0.920	.035	4	view →
CCRCC	DFS	Quartile	All	0.864	0.599	.031	2	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.854	.016	2	view →
HNSC	OS	Quartile	All	0.620	0.837	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DHX30–PDAC (OS)

Open the PDAC breakdown →